rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers (TSM-1)

Wayne State University

Status and phase: Withdrawn; Phase 2

Conditions: Healthy; Stress

Treatments: Device: sham rTMS; Drug: yohimbine + hydrocortisone; Device: medial prefrontal cortex rTMS; Drug: Placebo oral tablet

Study type: Interventional

Funder types: Other

Identifiers

NCT04180969

TSM-1

Details and patient eligibility

About

This study will be conducted with healthy male and female participants. Aim 1 will determine during sham repetitive transcranial magnetic stimulation (rTMS) how a drug stressor combination (yohimbine + hydrocortisone) relative to placebo alters : (1a) impulsivity; (1b) mood; and (1c) physiology. Aim 2 will determine whether active rTMS over the medial prefrontal cortex alters the effects of stress-exposure on (2a) decision-making, (2b) mood, and (2c) biomarkers of stress.

Full description

This study will use a double-blind, within-subjects randomized crossover design. Each participant will complete 4 sessions in this two-factor (2x2) combinatorial design: 1Hz medial prefrontal cortex (mPFC) vs. sham repetitive transcranial magnetic stimulation (rTMS) X pharmacological stressor (yohimbine 54mg + hydrocortisone 20mg) vs. placebo, with each session separated by at least 1 week. Participants will be asked not to use alcohol or drugs for 24-hr before arriving at the lab. We expect to complete screen at least 20 individuals to complete 12 individuals in this study. Candidates will first undergo psychiatric and medical screening to rule out contraindications to participation. Once enrolled, each participant will complete, in randomized order, the 4 conditions above. Periodic measures will be collected before and after the rTMS/sham and stress/placebo interventions. These measures will include subjective, behavioral and physiological assessments, as well as saliva and blood samples.

Sex: All

Ages: 21 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 21-60 yr
• Right-handed
• Males and non-pregnant/non-lactating females
• Cognitively intact (total IQ score >80 on Shipley Institute of Living Scale)
• Screening cardiovascular indices must be within ranges that allow for safe use of stressor: resting HR 50-90 bpm, systolic BP 90-140 mmHg, and diastolic BP 50-90 mmHg
• Use alcohol and/or marijuana <3 times/week; each "time" should consist of <1 marijuana "joint" equivalent and <3 alcoholic drinks

Exclusion criteria

• Under influence of any substance during session
• Past 7-day use of illicit drugs (excluding marijuana) based on Timeline Followback interview
• Urine positive for opioids, cocaine metabolites, benzodiazepines, barbiturates, amphetamines or pregnancy
• Medical conditions prohibiting use of rTMS (e.g. seizure history; using validated rTMS screening instrument)
• Lifetime diagnosis of: psychotic disorder, bipolar disorder, generalized anxiety disorder, obsessive compulsive disorder, or major depression that is not substance-induced
• Past-year substance use disorder
• Medical conditions making it unsafe for participation (e.g. neurological, cardiovascular, pulmonary, or systemic diseases)
• Lactose intolerance (placebo dose)
• Any prohibited medications: medications that lower seizure threshold, psychiatric medications, prescription pain medications, or blood pressure medications
• Chronic head or neck pain
• Taken part in any research studies in the past month

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

0 participants in 4 patient groups, including a placebo group

placebo stressor, sham rTMS

Placebo Comparator group

Description:

placebo stressor is lactose, and sham rTMS is inactive figure of 8 coil

Treatment:

Device: sham rTMS

Drug: Placebo oral tablet

placebo stressor, active rTMS

Experimental group

Description:

placebo stressor is lactose, and active rTMS is 1Hz stimulation over the medial prefrontal cortex

Treatment:

Device: medial prefrontal cortex rTMS

Drug: Placebo oral tablet

active stress, sham rTMS

Experimental group

Description:

active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and sham rTMS is inactive figure of 8 coil

Treatment:

Device: sham rTMS

Drug: yohimbine + hydrocortisone

active stress, active rTMS

Experimental group

Description:

active stressor is the combination of yohimbine 54mg + hydrocortisone 20mg, and active rTMS is 1Hz stimulation over the medial prefrontal cortex

Treatment:

Device: medial prefrontal cortex rTMS

Drug: yohimbine + hydrocortisone